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Abstract 
Dihydrofolate reductase (DHFR) is a member of the 
reductase enzyme family, which is ubiquitously 
expressed in all organisms. Levels of this enzyme 
peak at the G1/S cell cycle boundary. 
Autoregulation, through DHFR-RNA interactions, 
has also been reported. DHFR catalyzes the NADPH 
dependent reduction of dihydrofolate (DHF) to 
tetrahydrofolate (THF) needed for several one-
carbon transfer reactions in purine and pyrimidine 
synthesis (Jensen et al 1997, Klon   et al 2002). It is 
also the only enzyme that reduces folic acid, a 
synthetic vitamin not found in nature, to 
dihydrofolate (Banka et al. 2011). Reduction of 
DHFR enzymatic activity diminishes the THF pool 
inside the cell which slows DNA synthesis and cell 
proliferation eventually leading to cell death 
(Assaraf et al 2007, Klon et al 2002, Morales et al 
2009). DHFR inhibition is essential to the action of 
antifolate medications used to treat cancer and some 
inflammatory diseases. Changes in DHFR 
expression can affect susceptibility to a variety of 
diseases dependent on folate status such as spina 
bifida and cancer. Likewise, human DHFR (hDHFR) 
has become a major drug target in anticancer therapy 
(Klon   et al 2002, Sharif-Askari et al 2010). 
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Identity 
Other names: DHFRP1, DYR, EC 1.5 1.3 
HGNC (Hugo): DHFR 
Location : 5q14.1 
Location (base pair) 
Start at 80,626,226 and ends at 80,654,981 bp from 




DHFR encoded on chromosome 5 and has 6 exons 
which are separated by 5 introns.  
Chen et al (1984) determined that the DHFR gene is 
about 30 kb long and consists of 6 exons separated 
by 5 introns.  
The full length transcript is 28756 bp long and length 
of 3'-UTR of some human DHFR mRNA molecules 
was found to be 2900 nucleotides (Chen et al 1984). 
Transcription 
The human DHFR contains two promoters, the 
minor transcript which represents only 1% of DHFR 
mRNA molecules and the major transcript which 
codes for 99% DHFR mRNA.  
Independent regulation, low prevalence, nuclear 
enrichment and low translational efficiency suggest 
that the DHFR minor transcript may function in  
vivo to regulate the transcriptional activity of the 
major promoter (Blume et al 2003 and Martianov et 
al 2007). 
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Pseudogene 
The DHFR gene family includes the functional 
DHFR gene and four other intronless pseudogenes, 
dihydrofolate reductase pseudogene (DHFRP1-4), 
based on human-rodent somatic cell hybridization. 
Pseudogene-4 (DHFRP4) is assigned to 
chromosome 3, pseudogene-1 to chromosome 18 
with two transcripts and pseudogene-2 (DHFRP2) to 
chromosome 6 with one transcript (Anagnou et al. 
1984 and Anagnou et al. 1985). Interestingly, 
according to Anagnou et al. 1988 report, 
pseudogene-1 (DHFRP1) was found to be present in 
some individuals while completely absent in others 
with an interethnic variation in frequency which 
might implicate a recent origin in the evolutionary 
process (Anagnou et al., 1988).  
Recent studies suggest that DHFRP4, now known as 
dihydrofolate reductase-like 1 (DHFRL1) is 
expressed giving a functional protein product which 
shows a similar but less specific activity to that of 
DHFR enzyme (McEntee et al 2011). 
Protein 
Description 
Sequence length: 187 AA. Craik et al. (1983) in 
DHFR protein study reported that altered surface 
structures can account for functional differences 
among the members of a family. Also they pointed 
out that 'sliding' of the intron-exon junctions may 
design a mechanism for generating length 
polymorphisms and divergent sequences. 
Expression 
DHFR is extensively expressed in the fetal and adult 
tissues such as heart, liver, skeletal muscle, thymus, 
kidney, brains and whole blood with higher 
expression in adult brain in compare to fetal brain 
(Banka et al 2011). 
Localisation 
While the dihydrofolate reductase enzyme is thought 
to be present in multiple cellular compartments, it is 
most particularly localized in the cytosol and the 
nucleoplasm. 
Function 
DHFR is a key enzyme in folate metabolism as it is 
involved in 5,10-methylene tetra hydro folate (THF) 
generation from 7,8-dihydrofolate (DHF). The 
generated 5,10-methylene THF is used for the 
conversion of deoxyuridylate (dUMP) to 
deoxythymidylate (dTMP) in a reaction catalyzed by 
thymidylate synthase (TS). The regenerated THF 
starts subsequent rounds of thymidylate 
biosynthesis. Moreover DHFR contributes to the de 
novo mitochondrial thymidylate biosynthesis 
pathway and catalyzes de novo glycine and purine 
synthesis as well as DNA precursor synthesis 
(Anderson et al 2011 and Assaraf et al 2007). 
Homology 
Funanage et al (1984) assigned the DHFR gene to 
chromosome 5 and further narrowed the assignment 
to 5q11-q22. Based on their evidences, there is a 
homology between both the short and long arm of 
hamster chromosome 2 and human chromosome 5. 
Also, the sequences of the human and mouse DHFR 
proteins studied by Chen et al was shown to  differ 
in only 21 of 186 amino acids, which reflects an 89% 
homology in the DNA coding sequences of the genes 
(Funanage et al 1984 and Chen et al 1984). 
Mutations 
Germinal 
 Germline polymorphisms  
 1.  Location: Intron 1 
 Polymorphism:  19-bp insertion /deletion 
(rs70991108 
 Impact:  Low-serum folate/ high homocysteine, 
change in mRNA levels  
 Related disorders:  Neural tube defects and breast 
cancer  
 Note:  19 base pair deletion in intron 1 which 
elevated risk of developing breast cancer, neural-
tube defects (NTD) and may be a risk factor for low 
birth weight and preterm delivery (Xu et al 2007, 
Vander linden 2006 and Johnson et al 2005). In 
contrast, Parle-McDermott et al (2007), 
demonstrated that 19-bp deletion allele (D) may be a 
protective genetic factor against NTD by increasing 
DHFR mRNA levels in pregnant women. Moreover, 
a study by Rafighdoost also suggests that DHFR 19-
bp D/D genotype reduce the risk of Nonsyndromic 
cleft lip with or without cleft palate (NS-CL/P) in 
Iranian subjects (Rafighdoost et al. 2015).  
Ongaro et al (2009) and Vagace et al (2011) reported 
that homozygosity for DHFR 19 bp deleted allele 
polymorphism has been associated with increased 
hepatotoxicity in leukemia patients treated with 
MTX. 
 2.  Location: 3'-UTR  
 Polymorphism:  C829T, A721T, A1171T  
 Impact:  MTX resistance  
 Related disorder:  NTD and Rheumatoid Arthritis  
 Note:  C829T: Goto et al., (2001), by analyzing 3' 
untranslated region (UTR) of the human DHFR gene 
transcript discovered C829T substitution located 223 
base pairs downstream from the stop codon and 
positioned between the first and second 
polyadenylation site. It interferes with miR-24 
function leading to higher DHFR mRNA and protein 
levels. Present in 14.2% of the Japanese populations, 
the 829T/T mRNA expression level was found to be 
higher than 829C/C due to the higher stability of the 
T/T mRNA (Goto et al, 2001).  
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A721T did not have and significant association with 
NTD, but was found to be in complete linkage 
disequilibrium (LD) with the 19-bp indel 
polymorphism. (Parle-McDermott et al 2007).   
Sharma  et al (2009) demonstrated that DHFR 
A1171T (rs7387) polymorphism located in 3'UTR is 
considered as putative predictor for MTX response 
in rheumatoid arthritis patients.  
 3.  Location: Downstream to 3'UTR  
 Polymorphism:  A35289G (rs1232027) 
 Related disorder:  MTX efficacy in patients with 
psoriatic arthritis.  
 Note:  Chandran et al (2010) found an association 
of the A allele of A35289G polymorphism with 
MTX efficacy in patients with psoriatic arthritis.  
 4.  Location: Minor promoter  
 Polymorphism:   C-1610G or T (rs1650694) and 
A-317/G (rs408626)  
 Impact:  Higher DHFR expression  
 Related disorder:  Higher risk of relapse in ALL  
 Note:  Three polymorphisms in DHFR promoter in 
the 2 kb region upstream of the first or minor 
transcription of DHFR gene, (C-1610G/T, C-680A, 
and A-317G) were found associated with treatment 
responses in children with acute lymphoblastic 
leukemia (ALL). Haplotype 1 contains both the A-
317 and C-1610 alleles and conferred higher 
transcriptional activity, as shown by reporter gene 
assay and quantitative mRNA analysis, likely 
explaining a worse prognosis in patients carrying 
this haplotype. The ALL patients who were carriers 
of this haplotype had reduced event free survival 
(EFS) (Dulucq et al 2008).  
 5.  Location: Major promoter  
 Polymorphism:  G308A (rs1105525), C35T 
(rs1650697), Length polymorphism 63/91: 9-bp 
insertion deletion/ 9-bp repeat (rs3045983/ - )  
 Impact:  Higher DHFR expression  
 Related disorder:  Higher risk of relapse in ALL  
 Note:  Six polymorphisms including five SNPs, 
C35T, C304T, G308A, G319A, and A413G 
substitutions, along with one length polymorphism 
composed of two sequence motifs (i.e. 
insertion/deletion at position 63 and variable number 
of 9-bp elements at position 91), were identified in 
the major promoter of DHFR which participate in 
regulation as both a major promoter and a noncoding 
minor transcript. Haplotype 1b was identified as a 
haplotype responsible for the lower relapse-free 
survival observed in ALL patients. This haplotype is 
defined by C-1610, C-680, A-317 in the minor 
promoter and three alleles (T35, A308 and 
compound length polymorphisms composed of 9-
base pair (bp) insertion at position 63 and triple 9bp 
element at position 91) in the major promoter 
(Dulucq et al 2008 and Al-Shakfa, et al 2009).  
 6.  Location: Intron 3 
 Polymorphism:  A10372C (rs1677693) and 
A8890G (rs1643659)  
 Related disorder:  Colorectal cancer (Levine AJ et 
al 2010).  
 Polymorphism:  79940143T>C (rs1643650)  
 Related disorder:  Rheumatoid Arthritis  
 Note:  According to Salazar et al, this 
polymorphism was significantly associated with 
response to MTX in rheumatoid arthritis patients; 
patients with C/C and C/T genotypes showed a better 
response to treatment that those with T/T (Salazar et 
al 2014).  
 Mutations  
Location: 458A>T (Asp153Val)  
 Related disorder:  Megaloblastic Anemia.  
 Note:  Cario et al., 2011 reported a homozygous 
DHFR mutation, 458A>T (Asp153Val) that leads to 
DHFR deficiency which in turn results in a complex 
hematological and neurological disease that can be 
successfully resolved with folic acid or folinic acid 




Dihydrofolate reductase deficiency is an autosomal 
recessive metabolic disorder characterized by the 
hematologic findings of megaloblastic anemia and 
variable neurologic symptoms.  
A germline missense mutation in DHFR was 
identified causing subsequent extensive enzyme 
deficiency and resulting in an inborn error of 
metabolism which is characterized by megaloblastic 
anemia and/or pancytopenia, severe cerebral folate 
deficiency, and cerebral tetrahydrobiopterin 
deficiency (Banka  et al 2011). 
Neural tube defects (NTD) 
Neural tube closure occurs during a period of rapid 
cellular proliferation and DHFR activity may be a 
crucial factor in maintaining optimal DNA synthesis 
during this time. Changes in the activity of the folate 
cycle enzymes may affect the folate levels and affect 
NTD development. The most extensively studied 
DHFR polymorphism is a 19bp insertion to deletion 
in the first intron and two polymorphisms within the 
3' untranslated region (721A>T and 829C>T) of 
the DHFR gene (Parle-McDermott et al 2007). 
Rheumatoid Arthritis (RA) 
Response to treatment with Methotrexate in RA 
treatment was found to be influenced by the 
genotypes of the DHFR polymorphisms rs7387 
(Sharma  et al 2009) and rs1643650 (Salazar et al 
2014). 
Breast cancer 
The DHFR 19-bp deletion polymorphism affects the 
transcription of DHFR gene in humans which can 
modify the risk of breast cancer in multivitamin 
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supplement users. A multivitamin supplement has 
adverse effects in patients carrying the 19-bp 
insertion allele (Xu et al 2007). 
Colorectal cancer (CRC) 
Levine et al, 2010 demonstrated significant 
associations between two DHFR tagSNPs 
(rs1677693 and rs1643659, located on the third 
intron of the gene) and CRC risk only in individuals 
not using multivitamin supplements. 
Retinoblastoma 
Risk of retinoblastoma was significantly elevated 
among children of mothers homozygous for the 19bp 
deletion allele taking prenatal synthetic folic acid 
supplements (Orjuela, et al 2012). 
Nasopharyngeal carcinoma (NPC) 
DHFR has a significantly higher expression in NPC 
and is involved in NPC progression through the 
nucleotide biosynthetic process (Lee  et al 2013). 
Acute lymphoblastic leukemia (ALL) 
MTX is an important component of maintenance 
therapy in ALL, it exerts its cytotoxicity function by 
depletion of reduced folates due to interfering with 
folate metabolism.  Changes in DHFR expression 
level has been found to correlate with MTX efficacy 
in ALL (Ongaro et al 2009). Polymorphisms in 
DHFR gene may affect therapeutic responses to 
antifolates, leading to lower treatment efficacy or 
higher adverse drug event frequency. Particular 
haplotype (1b) increases mRNA levels of DHFR and 
was associated with a higher risk of ALL relapse. 
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